What is Rilpivirine?

Rilpivirine (TMC278, trade name Edurant) is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz.

Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011. A fixed-dose drug combining rilpivirine with emtricitabine and tenofovir, was approved by the U.S. Food and Drug Administration in August 2011 under the brand name Complera; it was licensed in the European Union under the brand name Eviplera in November 2011.

Questions and answers on "Rilpivirine"

I got urticaria 7 1/2 weeks into Complera. My doctor told me to stop taking it immediately just 4 days short of my next refill because of concerns...

doctor1 MD


Thanks for writing in.

Complera is emtricitabine / rilpivirine / tenofovir in oral tablet. This is an effective and well tolerated combination...

Read Full Thread   Ask a Doctor Now

Recently involved in a car wreck that left me with a sprained tibia. General Family Practice doctor prescribed me "Diclofenac" to help with the pain...

doctor1 MD


Thanks for the query

There are no known interactions between these two drugs however I would advice you to take a safer profile analgesic...

Read Full Thread   Ask a Doctor Now

Recent questions on Rilpivirine

Ask Question
Doctor Image

Hi, I am Dr. Andrew Rynne (Family Physician). I will be guiding you through the process. Please write your question below.

Related Disease & Conditions